Read the 2022 T3 Prescribing Report

We want to ensure that Integrated Care Boards follow the guidance rather than continue to refuse Liothyronine (T3) to patients who need it.

Levothyroxine is the standard medication for hypothyroidism but not all patients have their symptoms resolved with this and liothyronine (T3) can, in some patients, make a world of difference to their symptoms.

However, liothyronine needs to be prescribed by an endocrinologist, as per liothyronine guidance.

Thyroid UK, along with other partner thyroid organisations published a new T3 Prescribing Report which shows that 58% of Clinical Commissioning Groups (CCGs) in England are not following national guidance for liothyronine and that patients in those areas are being refused treatment with this important medication. The report calls on NHS England and the Department of Health to ensure that this postcode lottery is not allowed to continue.

CCGs are now transitioning to become Integrated Care Boards (ICBs) and it is essential that any patient that needs a trial of liothyronine has access to it. We want to ensure that ICBs follow the guidance rather than continue to refuse liothyronine to patients who need it.